Is Lactate Dehydrogenase An Important Mortality Predictor in Covid-19 Patients with Atrial Fibrillation?

INTRODUCTION: Abnormal laboratory parameters can be detected in severe patients with COVID-19, which are associated with adverse outcomes. Increased lactate dehydrogenase (LDH) is usually associated with tissue damage. Cardiovascular disease is a common comorbidity in COVID-19 disease. In the current report, the objective was to examine the relationship between LDH levels and atrial fibrillation (AF) in COVID-19 patients. METHODS: This investigation involved a retrospective and cross-sectional study. A total of 195 consecutive COVID-19 [45 AF (+) and 150 AF (-)] subjects were enrolled in the study. COVID-19 cases were determined from analysis of an oropharyngeal/nasopharyngeal swab using RT-PCR. LDH, procalcitonin, and D-dimer were recorded from the hospital records. RESULTS: Fatal patients had higher LDH levels compared to non-fatal patients (470+-144 vs 404+-60). A significant positive association was determined for LDH and troponin, CRP, and procalcitonin in all study subjects and AF patients. An LDH level of 443 was identified as the cut-off point in mortality of AF patients with a sensitivity and specificity of 73% and 74% (AUC= 0.744), respectively. LDH (OR: 1.009) and age (OR: 1.238) were shown to independently predict mortality in COVID-19-AF patients. DISCUSSION AND CONCLUSION: Increased LDH levels were essential predictor of mortality in COVID-19 subjects with AF. High LDH levels need careful observation to help prevent potential complications in COVID-19 subjects presenting with AF

Fibrinogen-to-albumin ratio predicts mortality in COVID-19 patients admitted to the intensive care unit

Introduction: Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two important factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU).Material and methods: Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin value. Mortality outcomes were followed up until December 15, 2020.Results: The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes mellitus (OR: 1.806; 95% CI: 1.142–2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR (OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients with COVID-19.Conclusions: The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU

Fibrinogen to albumin ratio as a powerful predictor of the exaggerated morning blood pressure surge in newly diagnosed treatment-naive hypertensive patients

Background The exaggerated morning blood pressure surge (MS) is a risk factor for cardiovascular diseases. Inflammation is associated with the pathogenesis of hypertension. We aimed to investigate the association between fibrinogen, albumin, fibrinogen to albumin ratio (FAR), and exaggerated MS, and which of those variables is a better predictor for identifying an exaggerated MS in newly diagnosed treatment-naive hypertensive patients. Material and Methods The study included 249 treatment-naive patients who were newly diagnosed with hypertension in both clinical and ambulatory blood pressure (BP) monitoring measurements. Morning BP was defined as the mean of BPs measured during the first 2 hours after wake-up. The lowest BP was defined as the mean of 3 BP measurements focused on the lowest nighttime computations. The MS was calculated as the morning systolic BP minus the lowest systolic BP. Fibrinogen and albumin levels were measured from venous blood. FAR was obtained by dividing the fibrinogen to the albumin. Results Patients with higher-value MS had a higher fibrinogen, FAR, and a lower albumin than those with low-value MS. MS was positively correlated with fibrinogen and FAR, and negatively correlated with albumin (for all, p < .001). Fibrinogen, albumin, and FAR were independent predictors of exaggerated MS. FAR was a more powerful predictor than fibrinogen (p < .001) and albumin (p = .02) in determining exaggerated MS. Conclusion Patients with exaggerated MS had a higher fibrinogen and FAR, and a lower albumin level than those without exaggerated MS. FAR may be a better predictor than fibrinogen and albumin for determining exaggerated MS

Fibrinogen-to-Albumin Ratio Predicts Mortality in COVID-19 Patients Admitted to the Intensive Care Unit

Introduction: Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two important factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU). Material and methods: Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin value. Mortality outcomes were followed up until December 15, 2020. Results: The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes mellitus (OR: 1.806; 95% CI: 1.142–2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR (OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients with COVID-19. Conclusions: The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU

Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarctionregistry in Turkey

Objective: the TURKMI registry is designed to provide insight into the characteristics, management from symptom onset to hospital discharge, and outcome of patients with acute myocardial infarction (MI) in Turkey. We report the baseline and clinical characteristics of the TURKMI population.Methods: the TURKMI study is a nation-wide registry that was conducted in 50 centers capable of percutaneous coronary intervention selected from each EuroStat NUTS region in Turkey according to population sampling weight, prioritized by the number of hospitals in each region. All consecutive patients with acute MI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018 and November 16, 2018.Results: A total of 1930 consecutive patients (mean age, 62.0±13.2 years; 26.1% female) with a diagnosis of acute MI were prospectively enrolled. More than half of the patients were diagnosed with non-ST elevation MI (61.9%), and 38.1% were diagnosed with ST elevation MI. Coronary angiography was performed in 93.7% and, percutaneous coronary intervention was performed in 73.2% of the study population. Fibrinolytic therapy was administered to 13 patients (0.018%). Aspirin was prescribed in 99.3% of the patients, and 94% were on dual antiplatelet therapy at the time of discharge. Beta blockers were prescribed in 85.0%, anti-lipid drugs in 96.3%, angiotensin converting enzyme inhibitors in 58.4%, and angiotensin receptor blockers in 7.9%. Comparison with European countries revealed that TURKMI patients experienced MI at younger ages compared with patients in France, Switzerland, and the United Kingdom. the most prevalent risk factors in the TURKMI population were hypercholesterolemia (60.2%), hypertension (49.5%), smoking (48.8%), and diabetes (37.9%).Conclusion: the nation-wide TURKMI registry revealed that hypercholesterolemia, hypertension, and smoking were the most prevalent risk fac-tors. TURKMI patients were younger compared with patients in European Countries. the TURKMI registry also confirmed that current treatment guidelines are largely adopted into clinical cardiology practice in Turkey in terms of antiplatelet, anti-ischemic, and anti-lipid therapy. (Anatol J Cardiol 2020; 24: 43-5

Profile of patients with acute myocardial infarction in Turkey: Results from TURK MI registry

Background and Aim:&nbsp;There is no up-to-date study representing Turkish population that gives information about patient profile, treatment choice and prognosis in patients with acute myocardial infarction (AMI). In this study, we present characteristics of AMI patients from a recently conducted TURKMI registry&nbsp;Methods:&nbsp;TURKMI registry included consecutive patients with acute coronary syndromes who were hos- pitalized between 1-15 November 2018 in 50 hospitals representing the country’s population based on 12 Euronuts regions. Demographic characteristics, risk factors, history of cardiovascular diseases and comor- bidities were recorded in each patients.Results:&nbsp;TURKMI Registry included 1930 patients [504 female (26.1%), 1426 male (73.9%), median (IQR) age 62 (53-71)]. Of those, 1191 (61.7%) had NSTEMI, and 739 (38.3%) had STEMI. NSTEMI patients were older (median age 63 (54-72) vs. 60 (51-69); p&lt;0.001). Most of the patients were male (71.3% for NSTEMI and 78.1% for STEMI). Diabetes, hypertension and hyperlipidemia were higher in NSTEMI patients; however, smoking was higher in STEMI patients (Table 1). History of MI, coronary bypass, percutaneous coronary intervention, and heart fail- ure were significantly higher in NSTEMI patients (Table 2). Among the associated disease, chronic obstructive pulmonary disease and chronic kidney disease were significantly higher in NSTEMI patients (Table 3).&nbsp;Conclusions:&nbsp;Most common risk factors in AMI were hypertension and smoking, each of them were avail- able nearly half of the patients. The third and fourth most common risk factor was diabetes and hyperlip- idemia, respectively. Distribution of risk factors differ in STEMI and NSTEMI patients. History of MI and coronary interventions were more common in NSTEMI patients.</div

Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarctionregistry in Turkey

Objective: The TURKMI registry is designed to provide insight into the characteristics, management from symptom onset to hospital discharge, and outcome of patients with acute myocardial infarction (MI) in Turkey. We report the baseline and clinical characteristics of the TURKMI population. Methods: The TURKMI study is a nation-wide registry that was conducted in 50 centers capable of percutaneous coronary intervention selected from each EuroStat NUTS region in Turkey according to population sampling weight, prioritized by the number of hospitals in each region. All consecutive patients with acute MI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018 and November 16, 2018. Results: A total of 1930 consecutive patients (mean age, 62.0 +/- 13.2 years; 26.1\% female) with a diagnosis of acute MI were prospectively enrolled. More than half of the patients were diagnosed with non-ST elevation MI (61.9\%), and 38.1\% were diagnosed with ST elevation MI. Coronary angiography was performed in 93.7\% and, percutaneous coronary intervention was performed in 73.2\% of the study population. Fibrinolytic therapy was administered to 13 patients (0.018\%). Aspirin was prescribed in 99.3\% of the patients, and 94\% were on dual antiplatelet therapy at the time of discharge. Beta blockers were prescribed in 85.0\%, anti-lipid drugs in 96.3\%, angiotensin converting enzyme inhibitors in 58.4\%, and angiotensin receptor blockers in 7.9\%. Comparison with European countries revealed that TURKMI patients experienced MI at younger ages compared with patients in France, Switzerland, and the United Kingdom. The most prevalent risk factors in the TURKMI population were hypercholesterolemia (60.2\%), hypertension (49.5\%), smoking (48.8\%), and diabetes (37.9\%). Conclusion: The nation-wide TURKMI registry revealed that hypercholesterolemia, hypertension, and smoking were the most prevalent risk factors. TURKMI patients were younger compared with patients in European Countries. The TURKMI registry also confirmed that current treatment guidelines are largely adopted into clinical cardiology practice in Turkey in terms of antiplatelet, anti-ischemic, and anti-lipid therapy